Market volatility is on everyone's mind but how can you protect your finances from the ebb and flow of the market? Chris Hutchins, Founder and CEO of Grove, joins Your Cheddar to discuss how to prepare yourself financially if you want to jump into investing. Hutchins recently launched Grove, a financial planning service that combines personalized financial advice and technology. He talks about why some people may want a human financial advisor rather than a robot or app. In addition, he predicts what the future of financial automation will be. Plus, Hutchins is a former partner at Google Ventures where he invested in multiple startups. He gives three pieces of advice for people looking to raise capital: have a passion for what you're doing, have a great team of people and produce a product that is proven to enhance the lives of customers using it.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More